- Home
- Media Center
- Press releases
- Innovative Medicine
Innovative Medicine
SYLVANT™ (siltuximab) Receives FDA Approval to Treat Multicentric Castleman’s Disease (MCD)
First treatment approved for patients with rare blood disorder
Final Data from the Phase 2 COSMOS Study of Janssen’s Once-Daily Simeprevir in Combination with Sofosbuvir Presented at The International Liver Congress™ 2014 of the European Association for the Study of the Liver (EASL)
Additional Studies Presented in Genotype 1 and Genotype 4 Hepatitis C Patient Subgroups Underscore Benefit of Simeprevir-based Treatment Regimens
Supplemental New Drug Application for IMBRUVICA™ (ibrutinib) Submitted to the U.S. FDA
New submission based on positive Phase 3 data from the RESONATE™ trial
Janssen Initiates Phase 3 OPTIMIST Trials of Once-Daily Simeprevir in Combination with Once-Daily Sofosbuvir for the Treatment of Genotype 1 Chronic Hepatitis C
OPTIMIST represents the first Phase 3 studies of the two treatments in a regimen without interferon and ribavirin
Anti-Interleukin-23 Monoclonal Antibody Guselkumab Shows Significant Efficacy In Treatment Of Moderate To Severe Plaque Psoriasis
Results from Phase 2b X-PLORE Study through Week 40 Report Efficacy of Guselkumab across Multiple Dosing Regimens and Compared with Adalimumab
Janssen Investigational Treatment for Schizophrenia Shows Positive Efficacy, Delays Relapse
Independent Data Monitoring Committee Recommends Halting Trial and Unblinding Data Based on Treatment Efficacy